FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281775557> ?p ?o ?g. }

• W4281775557 abstract "To explore the impact of seropositivity on systemic bone loss in rheumatoid arthritis (RA).We conducted an interim analysis of the RA registry. Patients were examined with dual-energy X-ray absorptiometry at baseline and again 3 years later. Participants were grouped into seropositive (SPRA) and seronegative (SNRA) based on the presence or absence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (ACPA). After matching (1:2) for age and sex, SNRA and SPRA patients were divided into groups A and B. Each matched group (A or B) was further subdivided according to the number of antibodies present (0, group I; 1, group II; 2, group III). Multiple ordinary least squares regression was used with the dependent variables to develop a model to predict bone mineral density (BMD) change.A total of 477 participants who completed a 3-year observation period were included. After matching, 312 participants were enrolled (group A, 104; group B, 208). Three years later, group B had significant BMD reduction in the femoral neck (FN) (p < 0.001), total hip (TH) (p = 0.001), and first through fourth lumbar vertebrae (L1-4) (p = 0.006), while group A had bone loss only at FN (p = 0.002). Groups I, II, and III included 104, 52, and 156 participants, respectively. Compared to baseline, BMD decreased significantly at FN (p = 0.002) in group I, FN (p < 0.001) in group II, and FN (p < 0.001), TH (p = 0.002), and L1-4 (p = 0.016) in group III. In terms of regression-adjusted percent change in BMD, more significantly negative changes were found at all measured sites in group B (p < 0.001, all) and at TH and L1-4 within groups I-III (p for trend < 0.001 and < 0.001, respectively). Regardless of antibodies, anti-osteoporotic therapy can preserve bone density in RA patients.After 3 years, SPRA patients lost more bone density than SNRA patients. More attention should be paid to SPRA patients, especially those with double-positive antibodies, including a vigorous evaluation of BMD and fracture risk. Anti-osteoporotic therapy can prevent BMD loss irrespective of autoantibodies." @default.
• W4281775557 created "2022-06-13" @default.
• W4281775557 creator A5007096831 @default.
• W4281775557 creator A5008444785 @default.
• W4281775557 creator A5012241630 @default.
• W4281775557 creator A5013176326 @default.
• W4281775557 creator A5019070557 @default.
• W4281775557 creator A5052821016 @default.
• W4281775557 creator A5063849726 @default.
• W4281775557 creator A5064924856 @default.
• W4281775557 creator A5076446661 @default.
• W4281775557 creator A5083197118 @default.
• W4281775557 date "2022-06-09" @default.
• W4281775557 modified "2023-10-16" @default.
• W4281775557 title "The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis—A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study" @default.
• W4281775557 cites W1968796843 @default.
• W4281775557 cites W1974718865 @default.
• W4281775557 cites W1978435955 @default.
• W4281775557 cites W1996443264 @default.
• W4281775557 cites W2010393347 @default.
• W4281775557 cites W2010402483 @default.
• W4281775557 cites W2024988150 @default.
• W4281775557 cites W2030561091 @default.
• W4281775557 cites W2032362610 @default.
• W4281775557 cites W2034267234 @default.
• W4281775557 cites W2043157906 @default.
• W4281775557 cites W2044178924 @default.
• W4281775557 cites W2060758238 @default.
• W4281775557 cites W2086103128 @default.
• W4281775557 cites W2101980834 @default.
• W4281775557 cites W2103991421 @default.
• W4281775557 cites W2110768118 @default.
• W4281775557 cites W2128952811 @default.
• W4281775557 cites W2132402446 @default.
• W4281775557 cites W2135583844 @default.
• W4281775557 cites W2149829914 @default.
• W4281775557 cites W2152348310 @default.
• W4281775557 cites W2167131572 @default.
• W4281775557 cites W2171709369 @default.
• W4281775557 cites W2177851274 @default.
• W4281775557 cites W2405362234 @default.
• W4281775557 cites W2416909860 @default.
• W4281775557 cites W2433359994 @default.
• W4281775557 cites W2594309628 @default.
• W4281775557 cites W2604970189 @default.
• W4281775557 cites W2786451037 @default.
• W4281775557 cites W2804088990 @default.
• W4281775557 cites W2809543483 @default.
• W4281775557 cites W2901863838 @default.
• W4281775557 cites W2903773433 @default.
• W4281775557 cites W2951486507 @default.
• W4281775557 cites W2974753117 @default.
• W4281775557 cites W3090385716 @default.
• W4281775557 cites W3111095973 @default.
• W4281775557 cites W3116382796 @default.
• W4281775557 cites W3134040436 @default.
• W4281775557 cites W3171291391 @default.
• W4281775557 cites W36216970 @default.
• W4281775557 cites W4211111012 @default.
• W4281775557 cites W2946172109 @default.
• W4281775557 doi "https://doi.org/10.3389/fmed.2022.885801" @default.
• W4281775557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35755026" @default.
• W4281775557 hasPublicationYear "2022" @default.
• W4281775557 type Work @default.
• W4281775557 citedByCount "0" @default.
• W4281775557 crossrefType "journal-article" @default.
• W4281775557 hasAuthorship W4281775557A5007096831 @default.
• W4281775557 hasAuthorship W4281775557A5008444785 @default.
• W4281775557 hasAuthorship W4281775557A5012241630 @default.
• W4281775557 hasAuthorship W4281775557A5013176326 @default.
• W4281775557 hasAuthorship W4281775557A5019070557 @default.
• W4281775557 hasAuthorship W4281775557A5052821016 @default.
• W4281775557 hasAuthorship W4281775557A5063849726 @default.
• W4281775557 hasAuthorship W4281775557A5064924856 @default.
• W4281775557 hasAuthorship W4281775557A5076446661 @default.
• W4281775557 hasAuthorship W4281775557A5083197118 @default.
• W4281775557 hasBestOaLocation W42817755571 @default.
• W4281775557 hasConcept C126322002 @default.
• W4281775557 hasConcept C168563851 @default.
• W4281775557 hasConcept C2775854910 @default.
• W4281775557 hasConcept C2776232647 @default.
• W4281775557 hasConcept C2776541429 @default.
• W4281775557 hasConcept C2776886416 @default.
• W4281775557 hasConcept C2777575956 @default.
• W4281775557 hasConcept C2777785397 @default.
• W4281775557 hasConcept C61943457 @default.
• W4281775557 hasConcept C71924100 @default.
• W4281775557 hasConcept C72563966 @default.
• W4281775557 hasConcept C90924648 @default.
• W4281775557 hasConceptScore W4281775557C126322002 @default.
• W4281775557 hasConceptScore W4281775557C168563851 @default.
• W4281775557 hasConceptScore W4281775557C2775854910 @default.
• W4281775557 hasConceptScore W4281775557C2776232647 @default.
• W4281775557 hasConceptScore W4281775557C2776541429 @default.
• W4281775557 hasConceptScore W4281775557C2776886416 @default.
• W4281775557 hasConceptScore W4281775557C2777575956 @default.
• W4281775557 hasConceptScore W4281775557C2777785397 @default.
• W4281775557 hasConceptScore W4281775557C61943457 @default.
• W4281775557 hasConceptScore W4281775557C71924100 @default.
• W4281775557 hasConceptScore W4281775557C72563966 @default.

• next